Vitamin E is an essential fat-soluble nutrient found in nuts, seeds, plant oils, avocado, leafy greens, and some fortified foods. It functions as an antioxidant and helps protect cell membranes from oxidative damage. Food sources of vitamin E belong in a healthy diet, but high-dose vitamin E supplements are a medical decision, not a general liver-health shortcut.
The liver condition once commonly called nonalcoholic fatty liver disease is now often called MASLD, or metabolic dysfunction-associated steatotic liver disease. Its more inflammatory form, formerly called NASH, is now often called MASH, or metabolic dysfunction-associated steatohepatitis. MASH can progress to fibrosis, cirrhosis, liver failure, liver cancer, or transplant need.
What The PIVENS Trial Found
The major vitamin E study behind this topic was the PIVENS trial, a randomized, double-blind, placebo-controlled trial in 247 adults with NASH who did not have diabetes. Participants received pioglitazone, natural vitamin E as rrr-alpha-tocopherol at 800 IU per day, or placebo for 96 weeks.
Vitamin E improved liver histology compared with placebo in this carefully selected group. At the end of the study, 43 percent of participants taking vitamin E met the primary endpoint, compared with 19 percent taking placebo. Pioglitazone also improved several liver features, but vitamin E met the prespecified primary outcome in the nondiabetic group.
Who May Benefit
Current liver guidance treats vitamin E as an option for some adults with biopsy-proven MASH who do not have diabetes and do not have cirrhosis. It is not a blanket recommendation for anyone with elevated liver enzymes, fatty liver on imaging, diabetes, alcohol-related liver disease, viral hepatitis, cirrhosis, or unexplained liver symptoms.
The distinction matters because abnormal liver tests can have many causes. Before considering high-dose vitamin E, clinicians usually need to confirm the diagnosis, assess fibrosis risk, review alcohol intake and medications, and evaluate metabolic risk factors such as weight, blood sugar, triglycerides, LDL cholesterol, and blood pressure.
Current Treatment Landscape
MASH treatment has changed since the original 2010 report. Diet, physical activity, weight loss when appropriate, and management of diabetes, cholesterol, blood pressure, and sleep apnea remain central. For some people, losing 7 to 10 percent of body weight can meaningfully improve liver fat, inflammation, and fibrosis risk.
There are now FDA-approved medications for adults with MASH and moderate-to-advanced fibrosis. Resmetirom, sold as Rezdiffra, was approved in 2024 for adults with noncirrhotic NASH/MASH with moderate to advanced liver fibrosis, used with diet and exercise. Semaglutide, sold as Wegovy, has also been approved to treat MASH in adults with moderate-to-advanced fibrosis. These approvals make it especially important that supplement decisions be made in the context of a full treatment plan.
Safety Concerns
Vitamin E from food is safe for most people. High-dose supplements are different. Vitamin E can increase bleeding risk, especially in people taking anticoagulants, antiplatelet drugs, or high-dose aspirin, and in people with bleeding disorders or vitamin K deficiency. It should be discussed before surgery or procedures.
Long-term high-dose vitamin E has also raised safety questions in large trials, including possible increased risk of hemorrhagic stroke and prostate cancer in some populations. People with a history of heart attack, stroke, prostate cancer risk concerns, diabetes, liver disease, or active cancer treatment should not start high-dose vitamin E without medical advice.
Food Sources Of Vitamin E
Good food sources include almonds, sunflower seeds, hazelnuts, peanuts, peanut butter, wheat germ oil, sunflower oil, safflower oil, spinach, Swiss chard, turnip greens, avocado, broccoli, olives, and fortified cereals. These foods also supply fiber, minerals, healthy fats, and other protective compounds.
Food sources are not the same as the 800 IU supplement dose used in MASH trials. A handful of almonds or seeds can support a nutrient-dense diet, but it will not reproduce the pharmacologic dosing studied in biopsy-proven MASH.
Final Note
Vitamin E has real evidence in a narrow MASH population, but it is not a universal liver-function supplement. The practical message is to eat vitamin E-rich foods as part of a balanced pattern, address the metabolic drivers of fatty liver disease, and use high-dose vitamin E only when a healthcare professional has confirmed that the likely benefits outweigh the risks.